Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4001316 | Urologic Oncology: Seminars and Original Investigations | 2006 | 5 Pages |
Abstract
The present case reminds the urologist that small-cell neuroendocrine carcinoma may be a variant form of disease recurrence during androgen ablation in advanced prostate cancer. A strategic approach for this phenotype evaluating serum neuroendocrine markers, such as ProGRP, should be taken when serum prostate-specific antigen does not reflect the disease state. This approach would allow one to choose alternative therapies targeting neuroendocrine cells other than androgen ablation.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Masahiro M.D., Fumihito M.D., Akinori M.D., Masanori M.D., Masayuki M.D., Yosuke M.D., Tatsuo M.D.,